CO-NEWMONT-CORPORATION
8.2.2024 14:31:30 CET | Business Wire | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) and Project C.U.R.E. announce a five-year agreement to deliver medical supplies and life-saving training for healthcare providers in developing countries and communities near Newmont mining operations. Under the agreement, Newmont commits to an annual contribution of $200,000 over the next five years, totaling $1 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208935869/en/
Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 countries. (Graphic: Business Wire)
“Creating a positive impact on more than 10 million people globally, through our partnership with Project C.U.R.E. is something we are incredibly proud of,” said Suzy Retallack, Newmont’s Chief Safety and Sustainability Officer. “For nearly two decades, our partnership has helped deliver support to host communities near our operations and around the world. We look forward to continuing to leverage our combined global reach to make a strong impact where it is needed most.”
Since 2005, Newmont has partnered with Project C.U.R.E. to distribute more than $42 million worth of much-needed medical supplies and equipment through multiple sponsorship initiatives. Highlights of the partnership include:
- Funding 108 shipping containers of medical equipment to 36 countries.
- Impacting more than two million patients through Newmont’s support of the C.U.R.E. Cargo program.
- Training more than 440 medical professionals, through the C.U.R.E. College program, in resource-limited environments to reduce neonatal and maternity morbidity and mortality.
- Contributing $5 million to support humanitarian efforts relating to the ongoing war in Ukraine, providing direct support to Project C.U.R.E., the American Red Cross and International Medical Corps.
- Delivering 164 C.U.R.E. kits – suitcase-sized, pre-packed kits of essential medical supplies – through Newmont employees to healthcare facilities in Ethiopia, Ghana, Indonesia, Mexico, Nicaragua, Peru and Suriname.
“We are proud of our partnership with the team at Newmont. For nearly two decades, we have worked together to save lives and strengthen the healthcare infrastructure for millions of people,” said Dr. Douglas Jackson, President and CEO of Project C.U.R.E. “In countries like Ghana and Suriname and now Mexico, Guatemala and others, we have established a figurative gold standard for corporate social responsibility and making our communities healthier, happier and more hopeful.”
Also, as part of Newmont’s partnership, employees around the world participate in myriad volunteer opportunities – logging hundreds of hours of time and service helping sort supplies at the Project C.U.R.E. warehouse, packing and unloading containers, and carrying medical kits to communities near Newmont operations.
About Project C.U.R.E.
Established in a garage in Evergreen, Colorado in 1987, Project C.U.R.E. has grown to be the world’s largest distributor of donated medical supplies and equipment to people living in developing countries. Since 2000, Project C.U.R.E. has delivered more than $1 billion of medical relief to save the lives of people facing poverty, disasters and violence. Project C.U.R.E. has worked in 138 countries, establishing an incredible footprint of medical relief around the world.
As a registered 501(c)(3), Project C.U.R.E.’s goal is to bridge the staggering health resource gaps in the developing world by empowering doctors and nurses with the tools they need—medical supplies and equipment—to treat disease, deliver vaccines, perform life-changing surgeries, and ensure safe childbirth. On average, Project C.U.R.E. delivers five forty-foot containers of donated medical relief each week.
About Newmont
Newmont is the world’s leading gold company and a producer of copper, zinc, lead, and silver. The company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in Africa, Australia, Latin America & Caribbean, North America, and Papua New Guinea. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social, and governance practices. Newmont is an industry leader in value creation, supported by robust safety standards, superior execution, and technical expertise. Founded in 1921, the company and has been publicly traded since 1925.
At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, go to www.newmont.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208935869/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
